Moore Capital Management, LP Intra Cellular Therapies, Inc. Transaction History

Moore Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $1.16 Million - $1.84 Million	25,000 New	25,000 $1.79 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $261,366 - $367,198	-6,121 Reduced 3.29%	180,185 $8.38 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $4.63 Million - $7.07 Million	107,638 Added 136.83%	186,306 $10.6 Million
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $63,223 - $101,330	-1,632 Reduced 2.03%	78,668 $4.81 Million
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $2.83 Million - $4.29 Million	80,300 New	80,300 $4.2 Million

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.